Sarcoma Foundation of America Honors Robert G. Maki, MD, PhD, with the Nobility in Science Award
Dr. Maki was recognized for his committment to finding a cure for sarcoma, a cancer of the connective tissue including bone, cartilage, muscle, and fat.
Robert G. Maki, MD, PhD, Medical Director of the Sarcoma Cancer Program at the Tisch Cancer Institute at The Mount Sinai Medical Center, and the Steven Ravitch Chair in Pediatric Hematology-Oncology, has been honored with the Nobility in Science Award at the 11th Annual Gala of the Sarcoma Foundation of America (SFA). Dr. Maki was recognized for his commitment to finding a cure for sarcoma, a cancer of the connective tissue including bone, cartilage, muscle, fat, and other soft tissue.
The Nobility in Science Award is given to an outstanding scientist who is dedicated to the advancement of scientific knowledge of sarcoma and works tirelessly to find new and innovative approaches for treating it. A leading sarcoma cancer researcher, Dr. Maki has made significant contributions to understanding soft-tissue and bone sarcomas and investigating new drug therapies that treat sarcomas by attacking molecular targets.
“We are so pleased to acknowledge Dr. Maki this year for his career focus and advancements in sarcoma research,” said SFA President Mark Thornton, MD, PhD.
Dr. Maki has expanded Mount Sinai’s basic and translational sarcoma cancer research programs, conducting clinical trials in adults with sarcomas, as well as translational studies in sarcoma biology to identify new targets for new drugs to treat sarcomas and other cancers. Dr. Maki is focused on developing and delivering personalized treatments and novel therapeutics to sarcoma patients, and exploring the biology that leads to different types of sarcomas. Additionally, as Chief of the Pediatric Hematology/Oncology Division, Dr. Maki is expanding the breadth of the pediatric clinical program in Hematology/Oncology at Mount Sinai, focusing on soft-tissue and bone sarcomas, adolescent cancer care, and transitioning pediatric cancer patients to adult care.
“On behalf of the people I have treated with sarcoma, I am honored to receive the Nobility in Science Award from the Sarcoma Foundation of America,” said Dr. Maki. “Since sarcomas are both rare and diverse, they are difficult to treat. The diagnosis of a sarcomas also adds a level of anxiety for people who get them, since so few people have even heard of them. The SFA is the group that has done the best job nationwide to unite people with these diagnoses to better understand and treat sarcomas. Thanks to the foresight of the SFA, the best research projects are supported through the funds they are able to raise, wherever those projects might be done.”
Dr. Maki earned his medical degree at Cornell Medical College in New York City and his PhD in immunology and molecular biology of sarcomas from Cornell University Graduate School of Medical Sciences in 1992, and completed an internship and a residency in internal medicine at Brigham and Women's Hospital in Boston. He went on to complete a medical oncology fellowship at Dana-Farber Cancer Institute, and later joined the Dana-Farber staff. Prior to joining Mount Sinai, Dr. Maki was an Associate Professor of Medicine at the Weill Cornell Medical College and Co-Director of the Adult Sarcoma Program at Memorial Sloan-Kettering Cancer Center, where he worked for 12 years before his move to Mount Sinai in 2011.
To learn more about Dr. Maki’s efforts and the Sarcoma Program at Mount Sinai, visit http://www.mountsinai.org/patient-care/service-areas/cancer/cancer-services/sarcoma-cancer-program.
The SFA is an advocate for increased research to find new and better therapies with which to treat patients with sarcoma. The organization raises money to privately fund grants for sarcoma researchers and conducts education and advocacy efforts on behalf of sarcoma patients. For more information, please visit www.curesarcoma.org.
About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Icahn School of Medicine at Mount Sinai. Established in 1968, the Icahn School of Medicine at Mount Sinai is one of the leading medical schools in the United States. The Icahn School of Medicine is noted for innovation in education, biomedical research, clinical care delivery, and local and global community service. It has more than 3,400 faculty members in 32 departments and 14 research institutes, and ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report.
The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation’s oldest, largest and most-respected voluntary hospitals. In 2012, U.S. News & World Report ranked The Mount Sinai Hospital 14th on its elite Honor Roll of the nation’s top hospitals based on reputation, safety, and other patient-care factors. Mount Sinai is one of just 12 integrated academic medical centers whose medical school ranks among the top 20 in NIH funding and by U.S. News & World Report and whose hospital is on the U.S. News & World Report Honor Roll. Nearly 60,000 people were treated at Mount Sinai as inpatients last year, and approximately 560,000 outpatient visits took place.
# # #